UVA1 Laser in the Treatment of Vitiligo

Babino, Graziella; Giunta, Alessandro; Esposito, Maria; Saraceno, Rosita; Pavlidis, Athanasios; Duca, Ester Del; Chimenti, Sergio; Nisticò, Steven Paul

doi:10.1089/pho.2015.4004

Cited by 9 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, one study evaluated the therapeutic safety lesions and on facial lesions, while acral lesions showed a slower response. 18 The poor response of acral lesions to UVA1 laser was similar to medium-dose UVA1 used in our study. Despite the advantage of shorter duration of sessions on using a UVA1 laser device in contrast to the long duration of the UVA1 session in our study which made it of low practicality, the results were nevertheless unsatisfactory.…”

Section: Discussionsupporting

confidence: 75%

“…Cumulative doses ranged between 1280 and 2240 J/cm 2 , for a total of 16 sessions, while in our study, cumulative doses ranged between 735 and 2140 J/cm 2 , for a total of 12 sessions. The response was better and faster on new lesions and on facial lesions, while acral lesions showed a slower response . The poor response of acral lesions to UVA1 laser was similar to medium‐dose UVA1 used in our study.…”

Section: Discussionsupporting

confidence: 72%

See 1 more Smart Citation

The role of long‐wavelength ultraviolet A1 (UVA1) in acral vitiligo

El-Zawahry

Elmasry

Ragab³

2018

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Summary Introduction Acral vitiligo is a resistant subtype of vitiligo that does not respond easily to any treatment modality. Ultraviolet A1 (UVA1) (340‐400 nm) therapy can penetrate the deep dermis of the skin and is relatively free of adverse effects associated with different phototherapeutic modalities. This study's objective was to evaluate the effect of medium‐dose long‐wavelength UVA1 (40‐70 J) in acral vitiligo treatment and compare it with topical psoralen plus ultraviolet A (topical PUVA). Methods Patients in this randomized‐controlled comparative clinical trial were divided into two groups, medium‐dose UVA1 group and topical PUVA group (10 acral vitiligo patients each). Patients received 36 sessions of phototherapy over a period of 12 weeks. Every patient was clinically evaluated monthly as regards the appearance of new lesions or increase in diameter of the current lesion according to point counting and vitiligo area severity index. Results No statistically significant clinical difference was found between patients in UVA1 and topical PUVA groups regarding response and pattern of response (P > 0.05). Conclusion Ultraviolet A1 seems to be of limited use as a monotherapy in acral vitiligo treatment. However, more studies combining it with other treatment modalities as systemic steroids and/or using higher UVA1 doses may prove beneficial.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionsupporting

confidence: 72%

The role of long‐wavelength ultraviolet A1 (UVA1) in acral vitiligo

El-Zawahry

Elmasry

Ragab³

2018

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…In contrast to the classical devices, Laser Alba 355® has the major advantages that, treating only skin lesions, it acts in a safer way reducing the side effects due to radiations and achieving better aesthetic results regarding less colour contrast between a vitiliginous and vitiliginous skin [ 9 ][ 10 ]. In our case, all patients treated with the innovative combination therapy achieved good results in term of repigmentation (repigmentation rate of 88%) without relevant side effects, apart from a transient inflammation and erythema.…”

Section: Discussionmentioning

confidence: 99%

An Innovative Therapeutic Protocol for Vitiligo: Experience with the Use of Fraxel Herbium Laser, Topical Latanoprost and Successive Irradiation with UVA - 1 Laser

Lotti¹,

Wollina²,

Tchernev³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Despite the continuous introduction of innovative therapies for vitiligo, today none of them provide constant and excellent results in term of repigmentation. The authors report their experience in treating a localised form of vitiligo with a new protocol consisting in the use of a Fraxel Herbium laser, and in the following application of topical Latanoprost solution and, one day after, in lesional irradiation with UVA1 laser.

show abstract

“…Babino et al 46 conducted an open-label, prospective study of 17 patients with vitiligo. The 355-nm UVA1 laser treatment was conducted twice weekly for 8 weeks at a fixed dose of 80-140 J/cm 2 .…”

Section: Clinical Studiesmentioning

confidence: 99%

Laser Treatments for Vitiligo

Bae

Hann²

2016

Medical Lasers

View full text Add to dashboard Cite

Vitiligo remains to be a major challenge in the field of dermatology. To this day, there is still no definitive cure. Although phototherapy has been the mainstay to manage vitiligo, it is associated with several adverse effects, such as tanning, burning, and skin aging, due to the unavoidable exposure of normal, uninvolved skin to intense ultraviolet radiation. Laser treatment has an advantage in treating vitiligo in a targeted way, and it appears to be a reasonable option for localized vitiligo. Moreover, a majority of patients have limited involvement of body surface area. An increasing number of reports have highlighted the value of lasers as a treatment option for vitiligo. The 308-nm xenon chloride excimer laser is already considered to be a treatment of choice for localized vitiligo. Additionally, there are emerging lasers that have been attempted as the treatment of vitiligo, including low-energy 632.8-nm helium-neon lasers, ablative fractional lasers, gain-switched 311-nm titanium:sapphire laser, and 355-nm monochromatic ultraviolet A1 laser. While evidences for these laser treatments of vitiligo are limited, some results seem to be promising. For example, studies have shown a responsiveness in otherwise refractory cases and via different mechanisms of action. However, most studies were uncontrolled and non-comparative, and have produced no conclusive results. Nonetheless, it is expected that we will witness greater development and advancement in laser treatments for vitiligo soon. In this article, we discuss the current state of laser treatments for vitiligo and proposed mechanisms of action.

show abstract

UVA1 Laser in the Treatment of Vitiligo

Abstract: the present report suggests that UVA1 laser could be an applicable therapeutic option in patients with vitiligo.

Cited by 9 publications

References 26 publications

The role of long‐wavelength ultraviolet A1 (UVA1) in acral vitiligo

The role of long‐wavelength ultraviolet A1 (UVA1) in acral vitiligo

An Innovative Therapeutic Protocol for Vitiligo: Experience with the Use of Fraxel Herbium Laser, Topical Latanoprost and Successive Irradiation with UVA - 1 Laser

Laser Treatments for Vitiligo

Contact Info

Product

Resources

About